This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at http://www.bbc.co.uk/news/uk-england-devon-26635909

The article has changed 5 times. There is an RSS feed of changes available.

Version 0 Version 1
Drug trial begins in Plymouth for cancer patients Bruton's Tyrosine Kinase drug trial offers cancer hope
(about 5 hours later)
Cancer patients in the South West, some terminally ill, are the first in the world to take part in a new drug trial. A cancer drug which clinicians hope can prolong the lives of terminally ill cancer patients has been trialled for the first time, a hospital trust says.
The aim is increase life expectancy for the severest forms of leukaemia and lymphoma without having chemotherapy. The trial, in Plymouth, is testing drugs called Bruton's Tyrosine Kinase (BTK) inhibitors to target the severest forms of leukaemia and lymphoma.
Professor Simon Rule, a consultant haematologist at Plymouth Hospitals NHS Trust, has led the study into a new class of Bruton's Tyrosine Kinase (BTK) inhibiting drugs. Prof Simon Rule, who led the study into the new class of drug, said it meant a "transformation" in treatment.
It has been taking place at Derriford Hospital in Plymouth. The trial began in the city in 2012 and has since extended worldwide.
Professor Rule, who also carried out research at Plymouth University, described it as "exciting" and "a transformation" in the treatment for patients with these conditions. The National Institute for Health and Clinical Excellence (NICE), which guides NHS trusts on treatments, declined to comment.
"The astonishing thing about these drugs is that they have virtually no side effects, which is unprecedented from my experience. In some patients the effects are immediate. Prof Rule, a consultant haematologist at Plymouth Hospitals NHS Trust, has been involved at the trial at Derriford Hospital and also carried out research at Plymouth University.
"Patients with lots of symptoms, particularly those with lymphoma, will feel better the next day after taking the medication," he said. "The astonishing thing about these drugs is that they have virtually no side effects, which is unprecedented from my experience. In some patients the effects are immediate," he said.
David Hodge, aged 74, from Plymouth, has suffered chronic lymphocytic leukaemia for 17 years. "Patients with lots of symptoms, particularly those with lymphoma, will feel better the next day after taking the medication," he added.
Prior to starting the trial in September 2012, Mr Hodge had been given only months to live with his immune system not functioning and becoming resistant to all other treatments. Prof Rule said the tablet-based drugs targeted the signalling pathways of a cell.
Mr Hodge said he took the medication first thing in the morning and then gets on with his day. "For the abnormal cells to survive they have to constantly tell themselves to live. If you interrupt the pathway, they die," he explained.
"I'm fighting fit. I've had no problems, no side effects, nothing. He added that normal cells were not dependent on this and it was specific to the cancerous cells.
'Fighting fit'
Plymouth Hospitals NHS Trust said the first four patients in the world to receive this drug were treated in the city as part of the trial, which started in September 2012.
Since then, more than 30 patients worldwide have received treatment, it added.
David Hodge, 74, from Plymouth, has suffered chronic lymphocytic leukaemia for 17 years.
Prior to starting the trial in September 2012, Mr Hodge had been given only months to live. His immune system was not functioning and becoming resistant to all other treatments.
Mr Hodge, who takes the medication every morning, said: "I'm fighting fit. I've had no problems, no side effects, nothing.
"I think with any new trial or drug, or with chemotherapy, there's a little bit of trepidation."I think with any new trial or drug, or with chemotherapy, there's a little bit of trepidation.
"I just felt, even if it proves at this moment, to be of little use to me; I trust that with 'fine tuning' it will prove to be significant to those taking the drug later on." "I just felt, even if it proves at this moment, to be of little use to me; I trust that with fine tuning it will prove to be significant to those taking the drug later on."